| Monoclonal antibody | |
|---|---|
| Type | Bi-specific T-cell engager |
| Source | Humanized |
| Target | CD20,CD3 |
| Clinical data | |
| Trade names | Ordspono |
| Other names | REGN1979; REGN-1979 |
| Drug class | Antineoplastic |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6458H9950N1728O2020S46 |
| Molar mass | 145593.47 g·mol−1 |
Odronextamab, sold under the brand nameOrdspono, is aCD20 xCD3 bispecificmonoclonal antibody that is used for the treatment offollicular lymphoma ordiffuse large B-cell lymphoma.[1][2] It was developed byRegeneron Pharmaceuticals.[1]
The most common side effects includecytokine release syndrome,infections,neutropenia,pyrexia (fever),anemia,thrombocytopenia, anddiarrhea.[1]
Odronextamab was approved for medical use in the European Union in August 2024.[1][2]
Odronextamab isindicated for the treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy;[1] and for the treatment of adults with relapsed or refractory diffuse large B‑cell lymphoma after two or more lines of systemic therapy.[1]
The most common side effects include cytokine release syndrome, infections, neutropenia, pyrexia, anemia, thrombocytopenia, and diarrhea.[1]
In June 2024, theCommittee for Medicinal Products for Human Use of theEuropean Medicines Agency adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Ordspono, intended for the treatment of follicular lymphoma and diffuse large B-cell lymphoma.[1][3] The applicant for this medicinal product is Regeneron Ireland Designated Activity Company.[1] Odronextamab was approved for medical use in the European Union in August 2024.[1][2][4]
Odronextamab is theinternational nonproprietary name.[5]
